Ventricular tachycardia from myocarditis following COVID-19 vaccination with tozinameran (BNT162b2, Pfizer-BioNTech).
Pacing Clin Electrophysiol
; 45(9): 1097-1100, 2022 09.
Article
in English
| MEDLINE | ID: covidwho-1752723
ABSTRACT
To combat the coronavirus disease 2019 (COVID-19) pandemic, many countries have started population vaccination programs using messenger ribonucleic acid (mRNA) vaccines. With the widespread use of such vaccines, reports are emerging worldwide, of the vaccine's association with the development of myocarditis. Younger men are more likely to develop postvaccine myocarditis, which usually presents as self-limiting chest pain within a week after the second dose. We present a case of myocarditis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech), which presented late, with ventricular tachycardia (VT) reduced left ventricular ejection fraction (LVEF).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Tachycardia, Ventricular
/
COVID-19
/
BNT162 Vaccine
/
Myocarditis
Type of study:
Case report
/
Observational study
Topics:
Long Covid
/
Vaccines
Limits:
Humans
/
Male
Language:
English
Journal:
Pacing Clin Electrophysiol
Year:
2022
Document Type:
Article
Affiliation country:
Pace.14486
Similar
MEDLINE
...
LILACS
LIS